SA PRO
Free Account
AARDAARD
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 100% recommend buying.

Consensus Rating
Buy
4 analysts·Low coverage
100%
Rating Distribution
Strong Buy
00%
Buy
4100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 137% higher.

Bear Case
$18.00
+38%
Consensus
$31.00
+137%
Bull Case
$47.00
+260%
Price Range4 analysts
Low
Consensus
High
$18.00
$47.00
Current Target
Current Price
$13.06
Upside to Target
$17.94

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Jan 12, 2026Raymond James
Raymond James Reiterates Strong Buy Rating on Aardvark Therapeutics Inc (AARD)
Target:$47.00
+229.4%from $14.27
Dec 23, 2025Oppenheimer
Aardvark Therapeutics initiated with an Outperform at Oppenheimer
Target:$35.00
+140.5%from $14.55
Nov 14, 2025RBC Capital
Aardvark Therapeutics Inc (AARD) PT Lowered to $18 at RBC Capital
Target:$18.00
+65.7%from $10.86
Sep 29, 2025Stifel Nicolaus
Aardvark Therapeutics initiated with a Buy at Stifel
Target:$24.00
+81.4%from $13.23
Mar 10, 2025Morgan Stanley
Aardvark Therapeutics initiated with an Overweight at Morgan Stanley
Target:$29.00
+190.6%from $9.98

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance